Michael Derby

Michael Derby General Information

Biography

Mr. Michael Derby is the Founder and serves as Managing Partner at TardiMed Sciences. He also serves as Executive Chairman at PaxMedica and Visiox Pharma. He served as executive Chairman at Anker Pharmaceuticals. He is also a Co-Founder and serves as a Board Member at Timber Pharmaceuticals. He also serves as a Board Member at Stamford Pharmaceuticals. He served as a Partner at Centerstone Partners. In 2015, he co-founded Castle Creek Pharmaceuticals which, under his leadership, raised more than $120 million and was built into a late clinical-stage company developing important therapies for patients with rare dermatologic conditions. Prior to Castle Creek, he founded Norphan Pharmaceuticals, which developed drugs for patients with rare neurologic diseases, including one of the first drugs to gain U.S. FDA approval for the treatment of Duchenne muscular dystrophy. Earlier in his career, he was a venture capitalist and operating executive, holding key commercial roles at Merck & Co. and Forest Laboratories. He holds advanced degrees in business and science, with an MBA, with distinction, from New York University's Stern School of Business, an MS in Neuroscience from the University of Rochester, and a BS, with honors, from Johns Hopkins University.